BI 3034701 (GLP-1/GIP/NPY2 Triple Agonist)

BI 3034701 is an investigational peptide designed to engage three receptors at once. Two of them are familiar: GLP-1 and GIP are the incretin receptors that tirzepatide targets, and their contribution to satiety, weight reduction and glycaemic control is well established. The third, NPY2, is the novelty.

The compound came out of a discovery collaboration with Gubra, a Danish peptide-focused company that has supplied several assets to larger developers. Boehringer Ingelheim holds sole responsibility for development and global commercialisation, with Gubra entitled to milestones and royalties.^[2] It sits alongside survodutide in Boehringer's obesity portfolio, which gives the company two structurally unrelated shots at the same market.

The Phase 1 programme was a randomised, placebo-controlled first-in-human study with two parts: healthy men aged 18 to 55 in Part A, and adults aged 18 to 65 with overweight or obesity in Part B, enrolling roughly 124 participants in total. Boehringer Ingelheim announced in December 2025 that the compound had shown a generally favourable safety and tolerability profile alongside encouraging weight-loss signals, and that the programme would advance.^[2]

Phase 2 began on 16 July 2026. The study is a dose-finding and broader efficacy and safety evaluation in people living with obesity and overweight, registered as NCT07662122.^[1] No efficacy magnitude from either phase has been published, and no readout date has been announced. BI 3034701 is investigational, is not approved anywhere, and is not commercially available.

The GLP-1 and GIP arms need little introduction. Dual agonism at those two receptors is the mechanism behind tirzepatide, and the case for combining them is settled by clinical evidence rather than argument.

NPY2 is where the reasoning gets interesting. The neuropeptide Y2 receptor is the target of PYY 3-36, a hormone released from the gut after eating that reduces food intake through central pathways. The site already covers the engineered PYY 3-36 analogs being developed to exploit that axis directly, and the long-standing question there is whether Y2 agonism adds anything on top of GLP-1 rather than duplicating it. Boehringer Ingelheim's framing is that NPY2 drives central control of hunger, appetite and food intake, complementing the satiety and metabolic regulation the incretin receptors deliver.^[1]

The company is careful about how far it takes this. Its own release describes NPY2 agonism as a potentially differentiated mechanism that is still under investigation, and notes that the effect on broader eating behaviour remains to be fully established. That is a more measured claim than the phrase "first-in-class triple agonist" implies on its own.

The contrast with the other triples is the useful frame. Retatrutide adds glucagon, which raises energy expenditure and mobilises liver fat, working on the output side of the energy equation. BI 3034701 adds NPY2, which works on the input side by suppressing hunger through a second, non-incretin route. Both are called triple agonists; they are attacking different halves of the problem.

BI 3034701 is the most mechanistically novel of the triple agonists, because it is the only one that leaves glucagon out and brings the NPY2 hunger pathway in. Phase 1 cleared, Phase 2 is running, and a major developer has committed to it alongside an existing late-stage obesity asset. What is missing is any number at all: no efficacy magnitude, no dose-response, nothing but the sponsor's adjectives. The Phase 2 dose-finding readout is the first point at which the NPY2 bet can be evaluated on evidence rather than rationale.